Hypoxia-inducible factor 1α (HIF-1α) plays a key role in mediating cancer cell malignant characteristics. Recent studies have shown that the histone demethylase JMJD2B is a target of HIF-1α, suggesting that histone methylation may be involved in tumor malignancy during hypoxia. However, little is known about the tumorigenic role of JMJD2B and its association with hypoxia in colorectal cancer (CRC). Furthermore, the downstream target genes and the mechanisms by which JMJD2B regulates its target genes in CRC during hypoxia remain to be clarified. Our results demonstrated that JMJD2B was induced under hypoxia in an HIF-1α-dependent manner in CRC cells. JMJD2B played an important role in CRC cell proliferation, apoptosis, cell cycle arrest and invasion, which could be modulated through upregulation of a subset of hypoxia-inducible genes expression by decreasing trimethylation of histone H3 lysine 9 on their promoters. We also showed that JMJD2B was overexpressed in CRC tissues and positively correlated with expression of the hypoxic marker carbonic anhydrase 9 (CA9), deeper depth of invasion and advanced clinical stages. Therefore, our findings suggest that JMJD2B may serve as a potential therapeutic cancer target.
Introduction
The initiation and progression of cancer, traditionally considered a consequence of genetic alterations, is now realized to be a process involving both epigenetic abnormalities and genetic changes (1) . Epigenetic dysregulations in cancer cells include aberrant DNA methylation, alterations in histone modifications, nucleosomal occupancy and remodeling, chromatin looping and non-coding RNAs. Histone methylation plays an important role in chromatin structural and DNA functional regulation (2) . Unlike histone acetylation, which is generally linked to transcriptional repression, histone methylation can be involved in either gene activation or silencing, depending on specific lysine sites. Additionally, histones can be mono-, di-or trimethylated, which may also have divergent effects on gene transcription. Specifically, trimethylation of histone H3 lysine 9 (H3K9me3) leads to transcriptional suppression, whereas di-and monomethylation on histone H3 lysine 9 (H3K9me2/me1) are associated with transcriptional activation (3, 4) . Furthermore, demethylation of H3K9me3 is believed to be maintained by a subgroup of JmjC domain-containing histone demethylases, the JMJD2 protein family, which includes JMJD2A, JMJD2B and JMJD2C (5, 6) .
Hypoxia is a common phenomenon in solid tumors, and hypoxia-inducible factor 1 (HIF-1) plays an essential role in mediating the cellular response to hypoxia through transcriptionally activating expression of hundreds of genes (7) . HIF-1 is a heterodimer consisting of the HIF-1α subunit and constitutively expressed 1β subunit. Under hypoxia, the HIF-1α subunit is stabilized and forms a functional HIF-1 heterodimer with the 1β subunit. The functional HIF-1 transcription factor specifically recognizes hypoxia response elements in the promoter of target genes, resulting in transcriptional activation. In hypoxic conditions, HIF-1α is dramatically elevated in cancer cells, thus contributing to metabolism shifting to anaerobic glycolysis, angiogenesis, cellular growth, apoptosis and an invasive phenotype (8, 9) . Besides directly regulating gene expression, HIF-1α has recently been identified to transactivate 4 JmjC domain-containing histone demethylases, including JMJD2B (10) (11) (12) (13) (14) . Therefore, HIF-1α may indirectly influence gene transcription at the level of histone methylation. However, the expression and the role of JMJD2B in response to hypoxia during the progression of CRC have not yet been clarified, and how JMJD2B modulates the transcriptional response to hypoxia remains to be fully investigated.
In this study, we investigated the role of JMJD2B induction by HIF-1α in proliferation, apoptosis, cell cycle arrest and invasion of CRC cells. Furthermore, the regulation by JMJD2B of a subset of hypoxia-inducible genes was studied. Additionally, expression of JMJD2B and the hypoxia marker carbonic anhydrase 9 (CA9) were detected in CRC tissues and correlated with certain clinicopathological characteristics, including the depth of invasion and clinical stages. Altogether, our results indicate that JMJD2B is a potential target for CRC therapy.
Materials and methods

Cell culture and hypoxia treatment
Human colon cancer cell lines SW480 and HCT116 were cultured in RPMI 1640 medium and McCoy's 5A medium (Gibco BRL, Gaithersburg, MD), respectively, supplemented with 10% fetal bovine serum. For hypoxia treatment, cells were incubated with 1% O 2 , 5% CO 2 and 94% N 2 in a hypoxia chamber (YCP-50S; Huaxi Electronic Technologies, Changsha, China) for 24 h.
RNA interference
All transfections were performed using the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. Sequences of HIF-1α and JMJD2B small interfering RNA (siRNA) were as described previously (15, 16) . The non-targeting control siRNA was purchased from GenePharma (Shanghai, China). HIF-1α and JMJD2B siRNA transfections were carried out in cells at 20% confluency 48 and 24 h, respectively, before hypoxia treatment.
Protein extraction and western blot analysis
Total cellular proteins were extracted using RIPA lysis buffer [50 mM Tris 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS] in the presence of a protease inhibitor cocktail (Kangcheng, Shanghai, China). Nuclear and cytoplasmic proteins were separated as described previously (17) . For western blotting assays, samples were mixed with 5× sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample loading buffer and heated at 100°C for 10 min. Proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). The membranes were probed with an anti-HIF-1α antibody (1:1000, BD Transduction Laboratories, Franklin Lakes, NJ), JMJD2B antibody (1:2000, Bethyl Laboratories, Montgomery, TX), α-tubulin antibody (1:1000, Cell Signaling Technology, Danvers, MA) and TBP antibody (1:1000, Abcam, Cambridge, UK). After incubation with the primary antibody overnight at 4°C, horseradish peroxidase-conjugated secondary antibodies (Kangcheng, Shanghai, China) at 1:5000 were used for 1 h at room temperature. Protein signals were detected with chemiluminescence (SuperSignal West Femto Maximum Sensitivity Substrate, Thermo Scientific, Rockford, IL). All the western blot analyses were repeated at least three times.
Abbreviations: CA9, carbonic anhydrase 9; ChIP, chromatin immunoprecipitation; CRC, colorectal cancer; HIF-1α, hypoxia-inducible factor 1α; qRT-PCR, Quantitative real-time reverse transcription-polymerase chain reaction; siRNA, small interfering RNA.
Carcinogenesis vol.33 no.9 pp.1664-1673, 2012 doi:10.1093/carcin/bgs217 Advance Access Publication June 27, 2012 Cell viability and invasion assays Cells were transfected with JMJD2B siRNA or negative control siRNA 24 h after passage into 96-well plates. Cells were then incubated either in normoxia (21% O 2 ) or hypoxia (1% O 2 ) for 48 h after transfection. Cell viability was evaluated at different time points using the Cell Counting Kit 8 (CCK-8, Dojindo, Kumamoto, Japan) according to manufacturer's instructions in triplicate and repeated three times. Alterations in cell invasiveness after JMJD2B knockdown in normoxia and hypoxia were assessed by matrigel invasion assays. At 24 h after transfection with JMJD2B siRNA, cells were counted, resuspended in 200 µl culture medium without fetal bovine serum and seeded into 8 µm inner chambers coated with matrigel (BD Biosciences, Franklin Lakes, NJ) at 1:3 dilutions. Culture medium (600 µl) supplemented with 20% fetal bovine serum was added to the lower chamber, and cells were allowed to invade for 24 h either in normoxia (21% O 2 ) or hypoxia (1% O 2 ). Cells were then fixed with 4% paraformaldehyde and stained with crystal violet. The invasion assays were repeated at least three times. The numbers of invasive cells including the cells invading through the pores of membrane and invaded onto the lower surface of porous membrane were counted in five randomized fields of vision. The evaluation of invasion assays was made in a blinded fashion.
Flow cytometry assays
In order to examine the effect of JMJD2B on apoptosis, SW480 and HCT116 were treated either in normoxia or hypoxia for 24 h after JMJD2B siRNA transfection. Thereafter, cells were collected and analyzed using the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, San diago, CA).
Meanwhile, cell cycles were tested after staining with propidium iodide. Both apoptosis and cell cycle assays were performed using a FACSCalibur (BD, San Diego, CA) and were repeated three times. The results are presented as means ± SD.
Gene microarray analysis
Total RNA was extracted from HCT116 cells using TRIzol (Takara, Shiga, Japan) according to the manufacturer's instructions. RNA was purified with the RNeasy mini kit (Qiagen, Hilden, Germany). Quality and quantity of purified RNA were evaluated by using the Agilent 2100 Bioanalyzer. Data were collected with the Affymetrix Human Genome U133 Plus 2.0 Array using standard methods and analyzed using GeneSpring GX Software. Three biological replicates were tested. Relative changes in gene expression were calculated to identify genes induced >2-fold under hypoxia, and genes decreased at least 0.5-fold after JMJD2B knockdown in hypoxia. These two groups were included into the Venn diagram to identify overlapping genes.
Quantitative real-time reverse transcription-polymerase chain reaction
Total cellular RNA was converted into cDNA with a RT reagent kit (Takara). Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was performed with the SYBR Premix ® Ex Taq II (Takara) on an ABI Prism 7300 Real-time PCR system (Applied Biosystems, Foster City, CA). Relative gene expression was calculated using the ΔΔC t method normalized to 18s rRNA expression. The primer sequences for qRT-PCR are listed in Supplementary Table 1, available at Carcinogenesis Online. Three replicates of qRT-PCR were performed, and repeated at least three times.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were performed following the manufacturer's protocols (Upstate, Temecula, CA), and repeated at least three times. In brief, HCT116 cells were cross-linked with 1% formaldehyde for 10 min at 37°C. Cells were lysed and sonicated to obtain fragmented DNAprotein complexes. Thereafter, cell lysates were centrifuged, and 200 µl of supernatant were diluted to 2 ml for immunoprecipitation. Samples were precleared with 75 µl of protein A agarose beads/salmon sperm DNA. An anti-H3K9me3 antibody (2.5 ng/µl, Abcam, Cambridge, UK) was used to immunoprecipitate the DNA-protein complexes. After a series of washes, cross-linking was reversed and DNA was extracted and purified for PCR. The primer sequences for ChIP are listed in Supplementary Table 2, available at Carcinogenesis Online.
Immunohistochemistry
Immunohistochemistry was performed on tissue microarrays containing 75 pairs of colon adenocarcinoma with corresponding normal colon epithelium to compare in situ expression of JMJD2B and hypoxia marker CA9. Antigen retrieval was performed by incubating slides in a citrate-ethylenediaminetetraacetic acid-based solution and heated for 10 min using a microwave. Sections were incubated with an antibody to either JMJD2B (1:200, Bethyl Laboratories, Montgomery, TX) or CA9 (1:200, Abcam, Cambridge, UK) at room temperature for 1 h, followed by horseradish peroxidase-conjugated goat anti-rabbit antibody. Antibody complexes were visualized with 3, 3′-diaminobenzidine, and sections were counterstained with hematoxylin.
The pathological evaluation was carried out by a single pathologist who was blinded to the final pathological interpretation.
Statistical analysis
Calculations were carried out using the statistical package for social sciences (SPSS) software. The t-test was performed for comparing the difference between two independent means. Although comparing the difference between three or more means, analysis of variance with Student-Newman-Keuls tests (SNK) were applied. Fisher exact test, chi-square test and non-parametric tests were used, depending on the data set of concern. P-values <0.05 were accepted as statistically significant.
Results
JMJD2B is hypoxia-inducible in a HIF-1α-dependent manner
As analyzed by western blot, JMJD2B was significantly upregulated in response to hypoxia (1% O 2 ) in SW480 and HCT116 cells, which was associated with elevated HIF-1α expression ( Figure 1A ). JMJD2B was predominantly localized in the nucleus under both normoxia (21% O 2 ) and hypoxia (1% O 2 ) ( Figure 1B) , consistent with its roles in epigenetic modulation and transcriptional regulation. To determine the involvement of HIF-1α in hypoxia induction of JMJD2B, we analyzed JMJD2B expression after siRNA knockdown of HIF-1α expression. As expected, loss of HIF-1α caused a reduction of JMJD2B expression. However, because gene silencing was incomplete and the hypoxic cells still expressed low levels of HIF-1α, we could not completely suppress the hypoxia induction of JMJD2B protein ( Figure 1C) . Collectively, these data indicated that JMJD2B could be upregulated in an HIF-1α-dependent manner during hypoxia in CRC cells. All bold values show P values less than 0.05, and were accepted as statistically significant.
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JMJD2B enhances CRC cell proliferation and invasion under both normoxia and hypoxia
To assess the role of JMJD2B in CRC cells, we used siRNA to specifically block its expression in SW480 and HCT116 cell lines ( Figure 2A ). Cell viability assays showed knockdown of JMJD2B impaired proliferation of CRC cells in normoxia and even more significantly under hypoxia ( Figure 2B ). To explore the reason for the reduced cell viability, we investigated the effects of JMJD2B on cell cycle transition and apoptosis. As illustrated in Figure 2C , cell cycle analysis revealed G 1 phase arrest in SW480 cells and G 2-M phase arrest in HCT116 cells after JMJD2B depletion, suggesting knockdown of JMJD2B expression caused cell cycle arrest depending on the cell type. We also identified significant CRC cell apoptosis with JMJD2B knockdown ( Figure 2D ). These results indicated that JMJD2B was indispensible for CRC cell survival, especially under hypoxic stress, and that JMJD2B promoted proliferation of CRC cells through inhibition of apoptosis and promotion of cell cycle progression. We then examined the effect of JMJD2B knockdown on invasiveness of CRC cells. As shown in Figure 2E , JMJD2B depletion significantly suppressed CRC cell invasion under both normoxia and hypoxia, suggesting JMJD2B was critical in mediating invasiveness of CRC cells.
Modulation of hypoxic gene expression by JMJD2B in CRC cells
In order to clarify the underlying mechanisms of JMJD2B function in CRC cells under hypoxia, HCT116 cells were transfected with Quantification of JMJD2B and HIF-1α levels (right). JMJD2B is predominantly nuclear and increased under hypoxia (*P < 0.05 versus normoxia). Cytoplasmic and nuclear JMJD2B band intensity were measured using ImageJ, normalized to α-tubulin and TATA-binding protein, respectively. (C) Hypoxia regulation of JMJD2B is HIF-1α-dependent. Representative western blot from negative control or HIF-1α siRNA transfected SW480 and HCT116 cells (left). Quantification of JMJD2B and HIF-1α levels (right). HIF-1α siRNA transfection resulted in a significant decrease in the level of JMJD2B and HIF-1α (*P < 0.05 versus negative control siRNA). Band intensities were measured using ImageJ, normalized to α-tubulin and presented as percentages relative to the levels of JMJD2B or HIF-1α with negative control siRNA, respectively. All data from at least three independent experiments are presented as mean ± SD.
L.Fu et al. negative control or JMJD2B siRNA and exposed to normoxia (21%) or hypoxia (1%), and gene expression was analyzed using the Affymetrix Human Genome U133 Plus 2.0 Array. The mRNA expression of JMJD2B was validated through qRT-PCR. As showed in Figure 3A , JMJD2B was significantly upregulated under hypoxia, and effectively downregulated transfected with siRNA against JMJD2B. Depletion of JMJD2B downregulated 450 genes (fold change < 0.5) in hypoxia ( Figure 3B , right circle), and 133 genes were upregulated under hypoxia (fold change > 2) ( Figure 3B , left circle). Of these genes, 20 were dependent on JMJD2B for full hypoxia induction ( Figure 3B , overlapping region). Functional annotations of these genes indicated that there were a number of differentially expressed genes with functions related to key cellular processes, including regulation of cell proliferation (SLC2A1, SLC2A3, ELF3, UCA1, MET, NOV), cell invasion (SLC2A1, ELF3, UCA1, MET, NOV), apoptosis (IFI6, MET), cell cycle (MET), glucose metabolism and formation of nucleosome structure (HIST1H2BD, HIST1H2BH, HIST1H2AC) ( Figure 3D ). The expression of JMJD2B-dependent hypoxia-inducible genes from the gene microarrays was confirmed using qRT-PCR ( Figure 3F ). Overall, these data suggest that by upregulating expression of proliferation, invasion, apoptosis and cell cycle related genes, hypoxia-induced JMJD2B promotes the progression and development of CRC.
Transcriptional upregulation by JMJD2B during hypoxia is mediated by decreased levels of H3K9me3 on promoters of target genes
An electrophoregram of DNA amplified from the ChIP samples incubated with H3K9me3-specific antibody, as well as the positive and negative controls, is shown in Figure 4A . The ChIP assays revealed significantly increased H3K9me3 levels on SLC2A1, ELF3, IFI6 and UCA1 promoters after JMJD2B depletion during hypoxia (P < 0.01) ( Figure 4B and 4C), indicating that JMJD2B directly bound to its target gene promoters and removed the repressive marker, thereby enhancing gene transcription. Meanwhile, H3K9me3 levels on the ELF3 and IFI6 promoters were significantly decreased under hypoxia compared with normoxia (P < 0.05 and P < 0.01, respectively; Figure 4B ), whereas those on SLC2A1 and UCA1 promoters showed a non-significant decrease in response to hypoxia (P = 0.063 and P = 0.056, respectively; Figure 4B ). Taken together, these data indicated that JMJD2B could activate transcription of proliferation-, apoptosis-and invasion-associated target genes through demethylation of the repressive H3K9me3 marker on their promoters, thus contributing to CRC cell progression under hypoxia.
Clinical assessment of JMJD2B and hypoxia status in CRC tissues
Expression of JMJD2B and hypoxia marker CA9 in CRC and nontumor adjacent tissues was determined by immunohistochemistry on tissue microarrays. JMJD2B and CA9 were expressed weakly in normal tissues ( Figure 5A and 5C), whereas they were overexpressed in CRC tissues ( Figure 5B and 5D ). Immunohistochemistry analyses of 56 CA9 + CRC tissue samples showed 38 cases (68%) with nuclear JMJD2B positivity, whereas in corresponding normal tissues showed only 8 cases (14%) with nuclear JMJD2B positivity (P < 0.05). These data showed that JMJD2B mainly localized in nucleus in hypoxic CRC 
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tissues, and the role of JMJD2B in tumorigenic phenotype may be associated with the nuclear localization with potential epigenetic activity.
In order to further confirm the relationship between hypoxia and JMJD2B in CRC tissues, colocalization of JMJD2B and the hypoxia marker CA9 was detected in serially cut whole sections ( Figure 5B and 5D). JMJD2B positively correlated with CA9 in CRC tissues (P = 0.027) (Table 1A) . Additionally, JMJD2B positivity was associated with elderly patients (P = 0.0038) (Table 1A) . However, no significant correlation was found between JMJD2B and pathological grade, lymph node status and distal metastasis (P = 0.57, 0.20 and 1.00, respectively) (Table 1A) . Furthermore, nuclear JMJD2B was positively associated with larger tumor sizes (P = 0.029), deeper depth of invasion (P = 0.023) and advanced clinical stages (P = 0.0008) ( Table 1B) , suggesting that the epigenetic function of nuclear JMJD2B may play important roles in CRC progression.
Discussion
With a high incidence and status as a leading cause of cancer death, CRC has received considerable research attention on its pathogenesis, prevention and treatment. CRC results from a sequential accumulation of genetic and epigenetic changes in colon epithelial cells, which transform them into adenocarcinoma (18, 19) . Although histone modifications play essential roles in processes such as transcription, replication and DNA repair, their importance in oncogenesis is not yet well established. However, several lines of evidence have suggested that histone methylation is involved in CRC development and progression (20) (21) (22) . Hypoxia is a common phenomenon in a wide range of solid tumors and is often associated with poor prognosis. In response to reduced oxygen tension, cancer cells undergo fundamental shifts in expression patterns of genes involved in proliferation, apoptosis, metastasis, invasion and energy metabolism, which ultimately result in cancer resistance to radiotherapy and chemotherapy (23) (24) (25) (26) (27) . HIF-1α is an essential component in altering the transcriptional response of tumors under hypoxia. Further investigations showed that HIF-1α expression occurs in the early stage of CRC and reaches a maximum in the invasive stage (28) . However, the majority of studies on hypoxia have been focused on the direct transcriptional regulation by HIF-1α. Although chromatin structures are known to effect gene transcription, little is understood about chromatin modifications and the downstream effectors under hypoxia. A recent study identified 17 out of 22 members of the JHDM family to be upregulated by hypoxia. Using ChIP-chip assays, the authors also demonstrated that four of them, including JMJD2B, are directly targeted by HIF-1α (13) . Furthermore, epigenetic regulation may work cooperatively with the HIF family or may contribute in a more substantial way to the maintenance of a hypoxia-adapted cellular phenotype long after HIF has initiated the immediate response pathways. Thus, it was proposed that epigenetics is the core of the hypoxia response (29) . Although overexpression of JMJD2B has been identified in several tumor tissues (13, 16) , very little was previously known about its expression and role in oncogenesis in CRC. Therefore, we investigated JMJD2B expression levels and relationship with HIF-1α in SW480 and HCT116 cells under normoxia and hypoxia. Our data showed that JMJD2B was u pregulated in hypoxia and correlated with HIF-1α expression. Meanwhile, HIF-1α knockdown via siRNA significantly reduced JMJD2B expression. In fact, the phenomenon that JMJD2B can be upregulated under hypoxia in an HIF-1α-dependent manner has been described in few other systems (10, 11, 13, 16) .
In order to confirm the association between JMJD2B and hypoxia in CRC tissues and to examine the potential involvement of JMJD2B in CRC pathogenesis, we further investigated the in situ expression of JMJD2B and hypoxic marker CA9 using tissue microarrays. We report here the significantly elevated levels of JMJD2B in CRC tissues compared with non-tumoral adjacent tissues. CRC tissues were frequently hypoxic compared with adjacent normal tissues, consistent with a previous report (28) . Additionally, in CRC tissues, JMJD2B showed a significant positive correlation with CA9 (P = 0.027). Since JMJD2B exerts its demethylase role in the nucleus, we further investigated the association of nuclear JMJD2B expression with clinicopathological variables. CRC tissues with nuclear JMJD2B positivity seemed to be associated with larger tumor size (P = 0.029), deeper depth of invasion (P = 0.023) and advanced clinical stages (P = 0.0008). These findings suggest that JMJD2B expression is positively associated with an intratumoral hypoxic status, and it may be involved in CRC proliferation, invasion and progression. Moreover, JMJD2B expression was positively in CRC tissues correlated with advanced patient age (P = 0.0038). It is possible that in elderly patients, the intestinal mucosa may be more susceptible to hypoxia (30) , and epigenetic lesions accumulate with aging (31). However, JMJD2B expression did not correlate with pathological grade, lymph node status or distal metastasis. Thus, further study should be conducted, and an increased number of cases may be necessary to clarify the potential oncogenic role of JMJD2B in CRC.
Unrestricted proliferation and local invasion are hallmarks of cancer. In response to hypoxia, upregulation of HIF-1α enhances the hypoxic metabolism shift to anaerobic glycolysis, epithelial-to-mesenchymal and remodeling of the extracellular matrix (13) , thereby contributing to cellular survival from hypoxia and promoting cancer cell invasion (32, 33) . Given that hypoxia induction of JMJD2B was shown to be HIF-1α-dependent, we presumed that JMJD2B may have oncogenic roles in CRC cells. Furthermore, a shRNA library-based functional genomic screen has identified JMJD2B as an essential growth gene in a number of human cell lines, although no further mechanistic characterization was performed (34) . Therefore, we tested the roles of JMJD2B in cancer development and progression in the SW480 and HCT116 cell lines. In vitro JMJD2B knockdown by siRNA impaired CRC cell proliferation under normoxia, and more significantly during hypoxia. Moreover, the decreased cell viability could be attributed to apoptosis and cell cycle arrest. The results of the invasion assays showed a significant decline in invasiveness of JMJD2B depleted CRC cells under both normoxia and hypoxia. Based on our findings, we hypothesized that JMJD2B may promote the CRC malignant phenotype through enhancing cell proliferation, cell cycle, apoptosis and expression of invasion related hypoxia-inducible genes. In order to identify those JMJD2B-dependent hypoxia-inducible genes in CRC cells, we employed human genome-wide microarrays. The gene microarray analysis identified 20 genes dependent on JMJD2B for full induction under hypoxia in HCT116 cells. Further functional annotations of the 20 JMJD2B-dependent hypoxia-inducible genes revealed that they play important roles in cancer cell proliferation, cell cycle, apoptosis, invasion and formation of nucleosome structure. Additionally, functional analysis revealed that JMJD2B regulates multiple cellular processes and signaling pathway under hypoxia ( Figure 3E ), suggesting that JMJD2B may be crucial for the adaptive response of CRC cells to hypoxia.
Our observations of SLC2A1, ELF3, IFI6 and UCA1 transcripts increasing during hypoxia and significantly decreasing after JMJD2B knockdown ( Figure 3F ) was consistent with the known ability of JMJD2B to specifically remove repressive H3K9me3 markers on target promoters (16, 35, 36) . We therefore postulated that the demethylase activity of JMJD2B is essential for transcriptional activation of target genes. As shown in Figure 4 , H3K9me3 levels on the promoter of these four genes were markedly increased after JMJD2B knockdown in hypoxia, indicating that JMJD2B can upregulate hypoxia-inducible genes expression through demethylating H3K9me3 on the promoters, thus contributing to CRC malignancy under hypoxia. Furthermore, H3K9me3 levels on the promoters of ELF3 and IFI6 were significantly decreased during hypoxia, consistent with the upregulation of these genes and induction of JMJD2B expression in hypoxia. Interestingly, in spite of an apparent increase in the expression of SLAC2A1 and UCA1 in hypoxia, we only observed a slight decline in the H3K9me3 status of the promoters. Recently, H3K9 demethylation and H3K4 methylation were found to be coordinated in ERα-activated transcription (35) . Thus, it is possible that the upregulation of genes in hypoxia are also modulated by other mechanisms besides reduction of H3K9me3 on promoters in CRC cells. However, the detailed mechanism remains to be thoroughly investigated.
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In conclusion, HIF-1α-dependent induction of JMJD2B is upregulated in CRC tissues, which can promote CRC cell proliferation, cell cycle, invasion and suppress cell apoptosis. Furthermore, JMJD2B upregulates hypoxia-inducible genes involved in cancer cell proliferation and invasion through specifically demethylating the promoter repressive H3K9me3. Our study suggests that JMJD2B plays a significant role in CRC tumorigenesis and progression. Further studies are necessary for targeting JMJD2B as a potential powerful approach to the development of novel epigenetic drugs, and may pave the way for developing new strategies for prevention and treatment of CRC.
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